Over 20 years after its creation on the Pomacle site, near the Bazancourt sugar refinery, ARD is inaugurating its new premises, just a few hundred metres away, at the centre of what has since become the biorefinery of Bazancourt-Pomacle.

Biopharmaceutical companies face high costs of clinical development for regulatory approval against a backdrop of increasingly fragmented reimbursement systems and assessment mechanisms unfit for the specificities of personalised therapies.